DERM NASDAQ
Journey Medical Corporation
1W: +7.7%
1M: -14.9%
3M: -8.4%
YTD: -11.3%
1Y: -8.8%
3Y: +144.8%
$6.61
-0.11 (-1.64%)
Weekly Expected Move ±8.6%
$5
$6
$7
$7
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships5
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2023-09-06
Earliest Filing
2026-02-23
Latest Filing
partner: 2
supplier: 2
licensee: 1
Counterparties (Filed by DERM)
5 relationshipsCompanies named in DERM's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Lake Street Capital Markets, LLC | — | partner | Sales agent/principal for at-market issuance of common stock | 2025-08-28 | View |
| Dr. Reddy's Laboratories, Ltd. | RDY | partner | Licensing partner and sponsor of the DFD-29 New Drug Application | 2024-07-12 | View |
| Maruho Co., Ltd. | — | licensee | Exclusive license agreement for Qbrexza in specified Asian territories | 2023-09-06 | View |
| Dermira | — | supplier | Original licensor of Qbrexza to Journey Medical Corporation | 2023-09-06 | View |
| Eli Lilly and Company | LLY | supplier | Parent company of Dermira, original licensor of Qbrexza | 2023-09-06 | View |
Mentioned As Counterparty
1 mentionsOther companies that named DERM in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-06-26 | Shareholder Vote | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-04-21 | Other Events; Exhibits | View | |
| 2026-03-25 | Earnings Release; Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-26 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation | Agreement | View |
| 2025-08-28 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Financial St | Agreement | View |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-14 | Other Events; Financial Statements and Exhibits | View | |
| 2025-06-26 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-06-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-03 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-03-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-02-05 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2024-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-04 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2024-07-12 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Departure/Electio | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR